An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Regulatory
FDA Grants Breakthrough Therapy Designation to Darovasertib in Melanoma
A phase 3 trial plans to further assess neoadjuvant darovasertib for the potential treatment of patients with primary uveal melanoma.
FDA Clears IND Application for CER-1236 in Advanced Solid Tumors
A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.
Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma
Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.